Bluejay Diagnostics Extends Cash Runway to Q2 2027, Reports $4.2M Net Loss
BJDX sits 27% above its 52-week low of $0.83 on light trading volume (0.1× avg).
Summary
Bluejay Diagnostics extended its cash runway to Q2 2027 after raising $8.5 million in June, but still needs $10-14 million more and faces ongoing going concern and Nasdaq delisting risks.
Key Events · Earnings and Guidance · BJDX
-
Cash Runway Extended to Q2 2027
Cash and cash equivalents rose to $9.6 million as of June 30, 2026, from $5.2 million at year-end 2025, extending the estimated runway from Q3 2026 to Q2 2027.
-
Net Loss of $4.2 Million
The company reported a net loss of $4.2 million for the six months ended June 30, 2026, compared to $3.8 million in the prior year period.
-
Additional Capital Needed
Management expects to raise between $10.0 million and $14.0 million by the end of fiscal 2027 to fund commercialization and manufacturing scale-up.
-
SYMON-II Enrollment Completed
Patient enrollment for the SYMON-II clinical validation study for IL-6 was completed in July 2026, with a 510(k) submission targeted for the first half of 2027.
Analysis · BJDX · Industrial Applications And Services
Bluejay Diagnostics reported a net loss of $4.2 million for the first half of 2026, but the key development is the extension of its cash runway. The company now estimates its $9.6 million in cash will fund operations through the second quarter of 2027, a significant improvement from the prior estimate of only through Q3 2026. This extension is directly tied to the $8.5 million private placement closed in June 2026. However, the company still expects to need an additional $10-14 million by the end of 2027, and the going concern warning remains in place. The filing also highlights progress on the SYMON-II clinical trial, with patient enrollment completed in July 2026, and a new US manufacturing agreement with Argonaut. The stock trades near $1.05, and the company faces a new Nasdaq delisting risk if a proposed $5 million minimum market value rule is approved.
At the time of this filing, BJDX was trading at $1.05 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.83 to $16.68. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.